Analysts think CUE stock price could increase by 462%
Aug 30, 2024, 6:25 AM
-6.48%
What does CUE do
Cue Biopharma, a Boston-based clinical-stage biopharmaceutical company, develops biologic drugs for immune system modulation to treat cancers and autoimmune disorders. Its key candidates include CUE-101 for HPV-positive HNSCC and CUE-102 for Wilms' Tumor 1 protein.
6 analysts think CUE stock price will increase by 461.60%. The current median analyst target is $4.08 compared to a current stock price of $0.73. The lowest analysts target is $2.02 and the highest analyst target is $6.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
